New Synthetic Antifungal Agents – K20 and Related Compounds

Technical Summary

•  Dr. Tom Chang and Dr. Jon Takemoto of Utah State University’s Chemistry/Biochemistry and Biology departments have developed a kanamycin derivative (K20) antifungal compound that inhibits candida, cryptococcus and other fungal species including azole-resistant strains.

•  K20 is a derivative of the aminoglycoside antibiotic kanamycin.  K20 is distinguished from the parent molecule kanamycin A by the presence of functional groups terminating in either an alkyl or phenyl group in the 6 position of ring III.  Structurally related compounds are also developed.  A preferred embodiment of K20 is the treatment of fungal infections of hosts wherein antifungal azole resistance is problematic.


Commercial Applications

•  Potential commercial partners:

•  Pharmaceutical companies

•  Medical and chemical supply companies

•  Agrichemical companies


Competitive Advantages

•  K20 derived from available parent molecule, kanamycin A

•  Novel antifungal mechanism of action

•  Low animal and plant toxicities and cytotoxicities

•  Scalable production at kg levels

•  Shows considerable inhibitory activity against several animal and plant fungal pathogens

•  May be administered through spraying, direct injection, topical application, oral administration, or by inclusion to the water supply


Additional Information




•  US 2012/0316125

•  US Patent 8,865,665


Related Technologies

•  New Synthetic Antifungal Agents – K20 and Azole-based Fungicides (P13013)

•  New Synthetic Antifungal Agents – Variations to kanamycin A, kanamycin B, and tobramycin (P14062)



Patent Information:
Agriculture and Food Science
For Information, Contact:
Christian Iverson
Utah State University
Cheng-Wei Chang Jon Takemoto